Absci Corp

NASDAQ:ABSIUnited States

Absci Corporation is a drug and target discovery company. The Company has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. It uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The Company has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. It has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.

Contact Information

Headquarters

18105 Se Mill Plain BlvdVANCOUVER, WA, United States 98683

Phone

360-949-1041

Fax

302-655-5049

Executives

Independent Chairman of the Board

Ivana Magovcevic-Liebisch

Chief Executive Officer, Founder, Director

Sean McClain

Chief Financial Officer

Gregory Schiffman

General Counsel and Corporate Secretary

Sarah Korman

Independent Director

Andreas Busch